For over a decade, the legal battle over talcum powder has been one of the most significant mass torts in American history. At Becker Law Group, led by Todd Becker, we have followed every twist of this litigation—from high-profile jury verdicts to complex bankruptcy maneuvers. As of May 2026, the landscape has shifted once again. With the "bankruptcy shield" strategies largely exhausted, the focus has returned to the courtroom and the negotiation table. Our mission is to ensure that "Your Fight Is Our Fight" as we seek accountability for women and families impacted by ovarian cancer.

The federal Talcum Powder Multidistrict Litigation (MDL 2738), centralized in the District of New Jersey, remains the largest active MDL in the United States, with over 67,000 cases currently pending. In early 2026, a critical ruling by the court-appointed special master reaffirmed that plaintiffs' experts can testify regarding the scientific link between genital talc use and ovarian cancer. The court found that newer epidemiological studies have actually strengthened the causal link, clearing the way for a new wave of federal bellwether trials scheduled throughout 2026.

After three failed attempts to resolve claims through "Texas Two-Step" bankruptcy filings, defendants like Johnson & Johnson are increasingly engaging in court-ordered mediation. As of May 2026:

Mesothelioma Claims: Approximately 95% of talc-related mesothelioma cases have been settled or are in advanced stages of resolution.

Ovarian Cancer Claims: While a global settlement for the 67,000+ ovarian cancer cases remains elusive, mediators are pushing for a multi-billion dollar resolution. Settlement values for individual cases in 2026 typically range based on age of diagnosis, length of product use, and severity of treatment.

State Court Success: Recent state court verdicts, including a $250,000 award in Pennsylvania and a $40 million bellwether verdict in California, continue to put immense pressure on defendants to reach a fair national agreement.

A major development in April 2026 was the formal retraction by the medical journal The Lancet of a 1977 commentary that had long been used by defense teams to argue for talc's safety. It was revealed that the document was authored by a consultant paid by the industry. This retraction removes a cornerstone of the defense’s "safe product" narrative, providing plaintiffs’ attorneys with significant new leverage in upcoming 2026 trials.

Yes. Despite the length of this litigation, the "discovery rule" in many states allows women diagnosed with ovarian cancer to file a claim if they only recently discovered the link between their diagnosis and talc use. At Becker Law Group, we provide a human-centric audit of your medical history and product use. "Protecting what you've built" includes ensuring that your family’s future is secured after a life-altering diagnosis.